Drug Approval | August 12, 2021
Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
A treatment to prevent extreme symptoms and cut hospitalisation
A treatment to prevent extreme symptoms and cut hospitalisation
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Company working on COVID vaccine INO 4800
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Deal for 100 million doses with additional 100 million through 2023
Subscribe To Our Newsletter & Stay Updated
